仙琚制药
(002332)
| 流通市值：102.79亿 | | | 总市值：103.27亿 |
| 流通股本：9.85亿 | | | 总股本：9.89亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,237,459,693.2 | 2,118,120,239.92 | 957,286,011.96 | 4,379,825,695.88 |
| 营业收入 | 3,237,459,693.2 | 2,118,120,239.92 | 957,286,011.96 | 4,379,825,695.88 |
| 二、营业总成本 | 2,682,439,708.51 | 1,742,468,048.76 | 794,203,612.8 | 3,643,765,754.83 |
| 营业成本 | 1,578,235,465.26 | 1,023,378,598.43 | 456,184,326.75 | 1,832,759,438.08 |
| 税金及附加 | 24,945,338.33 | 16,970,295.27 | 5,376,178.11 | 38,541,658.61 |
| 销售费用 | 726,839,396.07 | 459,303,836.02 | 221,187,541.25 | 1,262,803,999.27 |
| 管理费用 | 232,563,747.15 | 158,750,822.05 | 71,527,686.59 | 269,603,644.58 |
| 研发费用 | 139,459,816.96 | 93,399,257.85 | 41,335,925.3 | 266,768,087.11 |
| 财务费用 | -19,604,055.26 | -9,334,760.86 | -1,408,045.2 | -26,711,072.82 |
| 其中:利息费用 | 2,572,228.9 | 1,748,611.04 | 866,151.2 | 6,288,354.17 |
| 其中:利息收入 | 28,451,854.13 | 18,593,728.31 | 7,162,380.78 | 27,185,466.7 |
| 加:投资收益 | 11,388,764.38 | 8,636,641.4 | -1,184,263.5 | 49,354,016.59 |
| 资产处置收益 | -1,706,570.14 | -1,739,755.48 | -1,484,180.06 | 91,620,578.95 |
| 资产减值损失(新) | -27,493,892.98 | -27,522,261.97 | - | -32,163,141.91 |
| 信用减值损失(新) | -6,784,622.86 | -11,428,866.91 | -8,802,533.23 | -9,272,877.29 |
| 其他收益 | 14,679,570.78 | 9,923,572.21 | 1,844,285.45 | 42,998,487.99 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 545,103,233.87 | 353,521,520.41 | 153,455,707.82 | 878,597,005.38 |
| 加:营业外收入 | 3,549,162.67 | 2,194,950.92 | 1,121,389.69 | 1,481,741.73 |
| 减:营业外支出 | 5,363,737.55 | 4,156,863.05 | 896,749.23 | 8,187,240.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 543,288,658.99 | 351,559,608.28 | 153,680,348.28 | 871,891,507.08 |
| 减:所得税费用 | 71,336,528.35 | 50,594,382.67 | 24,382,784.77 | 124,505,936.78 |
| 六、净利润 | 471,952,130.64 | 300,965,225.61 | 129,297,563.51 | 747,385,570.3 |
| 持续经营净利润 | 471,952,130.64 | 300,965,225.61 | 129,297,563.51 | 747,385,570.3 |
| 归属于母公司股东的净利润 | 471,602,089.22 | 301,807,623.21 | 133,111,920.61 | 749,403,751.35 |
| 少数股东损益 | 350,041.42 | -842,397.6 | -3,814,357.1 | -2,018,181.05 |
| (一)基本每股收益 | 0.48 | 0.31 | 0.13 | 0.76 |
| (二)稀释每股收益 | 0.48 | 0.31 | 0.13 | 0.76 |
| 八、其他综合收益 | 25,335,128.82 | 70,357,893.31 | 14,438,696.65 | 21,719,405.33 |
| 归属于母公司股东的其他综合收益 | 25,335,128.82 | 70,357,893.31 | 14,438,696.65 | 21,719,405.33 |
| 九、综合收益总额 | 497,287,259.46 | 371,323,118.92 | 143,736,260.16 | 769,104,975.63 |
| 归属于母公司股东的综合收益总额 | 496,937,218.04 | 372,165,516.52 | 147,550,617.26 | 771,123,156.68 |
| 归属于少数股东的综合收益总额 | 350,041.42 | -842,397.6 | -3,814,357.1 | -2,018,181.05 |
| 公告日期 | 2023-10-26 | 2023-08-24 | 2023-04-26 | 2023-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |